Eli Lilly’s $300 Million Bridge: The Race to Dominate the Next Generation of Cancer Care
When a Big Pharma name enters a small biotech, there’s a certain silence. The founders...
When a Big Pharma name enters a small biotech, there’s a certain silence. The founders...